Subject: Prolotherapy*

Effective Date: March 23, 2004

Department(s): Utilization Management

Policy: Prolotherapy (also known as regenerative injection therapy) for musculoskeletal disorders is not reimbursable under Plans administered by QualCare, Inc.

Objective: To assure proper and consistent reimbursement and to exclude coverage of an unproven procedure.

Procedure:
- Requests for prolotherapy, regenerative injection therapy, or musculoskeletal sclerotherapy (HCPCS M0076) will be denied as unproven and thus experimental/investigational, on the basis of lack of adequate objective proof of efficacy in refereed medical literature.
- Denial of prolotherapy, regenerative injection therapy, or musculoskeletal sclerotherapy will apply irrespective of the professional credentials of the provider.

References


*Consistent with Summary Plan Description (SPD). When there is discordance between this policy and the SPD, the provisions of the SPD prevail.